Search clinical trials for: Aumolertinib monotherapy

Total 470 results

Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
Hansoh BioMedical R&D Company

Not yet recruiting

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Lung Cancer

China
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
EQRx, Inc.

Completed

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

NSCLC | Healthy Volunteers | Pharmacokinetics

United States, New Zealand
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Non-small Cell Lung Cancer

China
Kunming Medical University

Recruiting

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease

Recruiting

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Poor Performance Status | Malignant Tumor of Lung

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial (AUTUMN)

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. (APPROACH)

Lung Cancer

China
Shanghai Cancer Hospital, China

Recruiting

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Yuan Chen

Recruiting

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

NSCLC, Stage III

China
Sun Yat-sen University

Enrolling by invitation

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Safety of Almonertinib

China
Sun Yat-sen University

Recruiting

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Brain Metastases | Radiotherapy | EGFR Activating Mutation

China
Zhejiang Cancer Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases (ACHIEVE)

Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Metastatic Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance (APPEAR)

Safety

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Non Small Cell Lung Cancer | EGFR Activating Mutation | Stage III NSCLC

China
University of California, San Francisco

Not yet recruiting

Two-fraction HDR Monotherapy for Localized Prostate Cancer

Prostate Adenocarcinoma | Localized Prostate Carcinoma

United States
Xizang Haisco Pharmaceutical Co., Ltd

Recruiting

A Study for HSK39775 in Participants With Solid Tumors

Advanced Solid Tumors

China
Masonic Cancer Center, University of Minnesota

Active, not recruiting

HCW9218 in Select Advanced Solid Tumors

Solid Tumor

United States
Peking Union Medical College Hospital

Completed

Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

Chronic Periaortitis | Tocilizumab Monotherapy

China
Groupe d'Etude Therapeutique des Affections Inflammatoires...

Active, not recruiting

Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab (CURE)

CD

France, Belgium
PharmAbcine
C&R Research, Inc.

Recruiting

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

Korea, Republic of
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.

Completed

A Trial of ZL-1201 in Subjects With Advanced Cancer

Advanced Cancer

United States, China
Seoul National University Hospital
Threshold Pharmaceuticals

Completed

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Children's Hospital of Philadelphia
Bayer

Recruiting

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Cancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, Thyroid

United States
Brigham and Women's Hospital

Recruiting

Ultrasound Therapy In Cardiac Amyloidosis (UTICA)

Amyloidosis Cardiac

United States
First People's Hospital of Hangzhou

Not yet recruiting

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Brain Metastases | EGFR Positive Non-small Cell Lung Cancer

China
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
Tongji Hospital
First Affiliated Hospital Xi'an Jiaotong University; Wuhan Union Hospital,... and other collaborators

Recruiting

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Ovarian Cancer

China
Incyte Corporation

Terminated

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin's Lymphoma
Shenzhen TargetRx, Inc.
Institute of Hematology & Blood Diseases Hospital, China

Recruiting

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Non Hodgkin Lymphoma | Hematologic Malignancy | Acute Lymphoblastic Leukemia, Adult

China
EQRx International, Inc.

Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NSCLC

United States
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
Bryan Schneider, MD
Hoosier Cancer Research Network; Walther Cancer Institute; Vera Bradley Foundation... and other collaborators

Completed

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Breast Cancer | Malignant Neoplasm of Breast

United States
Shanghai Chest Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)

Lung Cancer | EGFR Gene Mutation
Assistance Publique - Hôpitaux de Paris
Novartis

Terminated

Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia (DAVASAB)

Nosocomial Infection | Healthcare-associated Infection

France
Sunnybrook Health Sciences Centre

Active, not recruiting

MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients (MARS)

Prostate Cancer

Canada
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy (REDEEM-2)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Malaysia, South Africa, Korea, Republic of

Search clinical trials for: Aumolertinib monotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations